Post-Febrile Neuralgia Treatment
For post-herpetic neuralgia (the condition following herpes zoster/shingles), initiate treatment with gabapentin or pregabalin as first-line therapy, titrating to 2400 mg/day (gabapentin) or 300-600 mg/day (pregabalin) in divided doses. 1
First-Line Pharmacological Options
The evidence strongly supports a stepwise approach:
Primary First-Line Agents
Gabapentin: Start at 100-300 mg at bedtime, titrate to 2400 mg/day in 3 divided doses (typical effective range: 900-3600 mg/day). This has strong evidence (NNT = 4.39) for post-herpetic neuralgia 1. Somnolence occurs in 80% of patients but improves sleep scores 1.
Pregabalin: Start at 25-50 mg/day, titrate to 150-600 mg/day in 2 divided doses (NNT = 4.93). Superior pharmacokinetics allow easier and faster titration than gabapentin 1, 2.
Tricyclic Antidepressants (TCAs): Nortriptyline preferred over amitriptyline due to fewer side effects. Start 10-25 mg at bedtime, increase every 3-7 days to 25-100 mg at bedtime (NNT = 2.64) 3, 1. Demonstrated 66% pain reduction within 3 weeks in post-herpetic neuralgia trials 3. Critical caveat: Use with caution in cardiac disease; limit to <100 mg/day when possible 4.
Topical First-Line Options (for localized pain)
Capsaicin 8% patch: Single 30-60 minute application provides relief for up to 12 weeks (NNT = 3.26). Pre-treat with 4% lidocaine for 60 minutes to reduce application pain 1.
Lidocaine patches 5%: Apply to affected area (NNT = 2) 1.
Second-Line Options (if inadequate response to first-line)
If gabapentin/pregabalin fails after adequate trial at target doses:
- Add or switch to TCAs (nortriptyline) 4, 1
- Serotonin-norepinephrine reuptake inhibitors (SNRIs): Duloxetine or venlafaxine based on general neuropathic pain efficacy 1
- Tramadol: 200-400 mg/day in divided doses (NNT = 4.76) 1
Third-Line/Salvage Options
Opioids: Only after first-line failures; use lowest effective dose. Evidence shows NNT = 2.67 for oxycodone, extended-release morphine, or methadone in post-herpetic neuralgia 1. Not recommended as first-line due to addiction risk, cognitive impairment, and potential pronociception 1.
Carbamazepine: Start 200 mg at night, increase by 200 mg every 7 days to 400-1200 mg/day in 2-3 divided doses. Primarily used for trigeminal neuralgia but may help refractory cases 3.
Treatment Algorithm
Step 1: Initiate gabapentin (titrate to 2400 mg/day) OR pregabalin (titrate to 300-600 mg/day)
- If localized pain: Add topical lidocaine or capsaicin 8% patch
Step 2 (if <30% pain reduction after 2-4 weeks at target dose):
- Switch to nortriptyline (25-100 mg at bedtime) OR
- Add nortriptyline to gabapentinoid
Step 3 (if combination therapy fails):
- Add tramadol OR
- Consider SNRI (duloxetine/venlafaxine)
Step 4 (refractory cases):
- Time-limited opioid trial OR
- Referral to pain specialist for interventional options
Critical Timing Considerations
Early antiviral therapy within 72 hours of rash onset reduces acute disease severity and may decrease PHN risk 5, 6. However, once PHN is established (pain persisting >3 months after rash healing), antivirals are no longer effective.
Common Pitfalls
- Starting doses too high: Elderly patients require lower starting doses (pregabalin 25 mg, gabapentin 100 mg) to minimize sedation and dizziness 2
- Inadequate trial duration: Allow 2-4 weeks at therapeutic doses before declaring treatment failure 7
- Ignoring topical options: Topical therapies have superior safety profiles due to minimal systemic absorption and should be used whenever feasible 2
- Premature opioid use: Opioids should not be first-line; exhaust gabapentinoids and TCAs first 1
Adjunctive Non-Pharmacological Options
- Cognitive behavioral therapy (strong evidence) 1
- Physical/occupational therapy 1
- Transcutaneous electrical nerve stimulation (TENS) 8
Monitoring
Reassess pain intensity and quality of life every 2-4 weeks. Target is average pain ≤3/10 with tolerable side effects 4. If pain remains ≥4/10 after adequate first-line trial, escalate per algorithm above.